Publications by authors named "Niti U Trivedi"
Background: The National Comprehensive Cancer Network (NCCN) financial conflict of interest (FCOI) policy sets dollar maximums for panelists, but violations may occur.
Methods: We studied NCCN Guidelines panelists for the 20 most prevalent cancers, 2013-2022. We included panelists with ≥1 calendar year of service ("current panelists") and those who began service during the study period ("new panelists"); NCCN FCOI policy limits ($20,000 from any single company or $50,000 across all companies) applies to both groups.
Article Synopsis
- The Medicare part D Low-Income Subsidy (LIS) helps with oral cancer drugs but doesn't support clinician-administered drugs, highlighting a gap in cancer treatment assistance.
- An analysis using SEER-Medicare data from 2015-2017 found that LIS participants had lower odds of receiving any systemic therapy and tended to receive less effective treatments compared to non-LIS participants.
- Overall, the study suggests that LIS may negatively impact access to optimal cancer treatment, leading to worse outcomes for certain patients.
Background: Industry payments to US cancer centers are poorly understood.
Methods: US National Cancer Institute (NCI)-designated comprehensive cancer centers were identified (n = 51). Industry payments to NCI-designated comprehensive cancer centers from 2014 to 2021 were obtained from Open Payments and National Institutes of Health (NIH) grant funding from NIH Research Portfolio Online Reporting Tools (RePORT).
Article Synopsis
- The study aimed to analyze how payments from pharmaceutical companies to oncologists affect the use of non-recommended or low-value cancer treatments in patients.
- It examined Medicare beneficiaries diagnosed with cancer between 2014 and 2019, focusing on specific treatments like denosumab and GCSF that have been deemed unnecessary or ineffective for certain patients.
- Results showed that a significant percentage of oncologists who received industry payments prescribed these low-value drugs, with varying rates of payment received across different treatment types.
The September 11, 2001, terrorist attacks on the World Trade Center (WTC) in New York City (9/11) had health-related consequences, including posttraumatic stress disorder (PTSD). PTSD is associated with functional impairment, which varies by symptom severity and other factors. This study aimed to identify predictors of functional impairment in individuals with low versus high PTSD symptom severity levels.
View Article and Find Full Text PDFBackground: Drug manufacturers claim that the purpose of financial payments to physicians is to facilitate education about new drugs. This claim suggests 2 testable hypotheses: payments should not be associated with drug revenue and payments for each drug should decline over time as physicians become educated.
Materials And Methods: We used open payments data on industry payments.
Background: The Prescription Drug User Fee Act (PDUFA) is due for reauthorization in 2022. Beyond creating the user fee program which now generates a majority of the Food and Drug Administration (FDA) Human Drugs Program budget, PDUFA has made numerous additional changes to FDA policy during its 29-year history. FDA's budgetary dependence on user fees may advantage the industry in negotiating favorable policy changes through PDUFA.
View Article and Find Full Text PDFIncreasing Financial Payments From Industry to Medical Oncologists in the United States, 2014-2017.
J Natl Compr Canc Netw
December 2021
Background: Personal payments from the pharmaceutical industry to US physicians are common and are associated with changes in physicians' clinical practice and interpretation of clinical trial results. We assessed temporal trends in industry payments to oncologists, with particular emphasis on payments to authors of oncology clinical practice guideline and on payments related to immunotherapy drugs.
Methods: We included US physicians with active National Plan and Provider Enumeration System records and demographic data available in the Centers for Medicare & Medicaid Services Physician Compare system who had a specialty type of medical oncology or general internal medicine.
Article Synopsis
- The study investigated the financial relationships oncologists have with pharmaceutical companies, specifically whether those involved in clinical practice guideline committees receive more industry payments compared to those who do not.
- Researchers analyzed data from a case-control study involving oncologists on National Comprehensive Cancer Network (NCCN) committees to compare payments received before and after joining the committee.
- Results showed that oncologists who joined these committees received significantly higher payments before joining, but their financial ties did not increase post-appointment, raising concerns about potential conflicts of interest in clinical guidelines.
Background: Financial payments from the drug industry to U.S. physicians are common.
View Article and Find Full Text PDF